Is there any evidence that patients with metastatic NSCLC with KRAS G12C mutations benefit less from treatment with immunotherapy?   

KRAS mutation in NSCLC has been associated with improved response rate and overall survival compared to KRAS wild type NSCLC in meta-analysis of single-agent, second-line trials with PD-1/PD-L1 inhibition. Moreover, analysis of patients with KRAS lung adenocarcinoma divided by subsets including co-m...

On the contrary, KRAS mutations, in general, have been associated with deriving prolonged survival from immunotherapy compared to KRAS wildtype group in subgroup analysis of CM057 as well as other immunotherapy trials (e.g. Lee et al., PMID 29270615, West et al., PMID 35190375).Data pertaining to re...

The biology of KRAS G12C seems to be different from other traditional driver alterations such as EGFR and ALK where there is limited benefit of single agent immunotherapy. There is data to show that those with G12C may actually have more benefit with immunotherapy. Indeed, the subgroup analysis of K...

The data for using immunotherapy in patients whose tumors harbor KRAS G12C mutations is complex and we are continuing to learn more. Specifically, we have to take into account markers that can indicate the potential for IO benefit such as PD-L1 expression and TMB status, as well as important co-muta...

The FDA approved Sotarasib based on results from a subset of patients in CodeBreaK100, exclusively for patients with the KRAS G12C mutation showing favorable efficacy and tolerability for patients with KRAS G12C mutation-positive NSCLC who had disease progression after receiving immunotherapy a...